With a focus on AML due to the greater need for efficient therapies, we confirmed the role of CaSR for AML development by efficiently rescuing the disease in recipient mice by CaSR overexpression in CaSR KO MLL-AF9+ BM cells (P = 0.0237, Fig. 3e, Supplementary Fig. 10g, h). Here, KMT2A is linked to acute myeloid leukemia.